AI Article Synopsis

  • Infiltrative hepatocellular carcinoma (HCC) presents poorer prognosis compared to non-infiltrative HCC, complicating treatment decisions, particularly with immunotherapy using immune checkpoint inhibitors (ICIs).
  • A study of 198 unresectable HCC patients showed similar treatment responses for infiltrative (ORR 36.7%) and non-infiltrative (ORR 33.3%) groups, but infiltrative HCC patients had significantly shorter progression-free survival (4.1 months) and overall survival (10.4 months) than those with non-infiltrative HCC (5.5 months PFS and 17.0 months OS).
  • Findings suggest that while immune responses to ICIs are comparable

Article Abstract

Background: Infiltrative hepatocellular carcinoma (HCC) is often associated with an unfavorable prognosis, posing a challenge in determining the optimal therapeutic approach. Immunotherapy, employing immune checkpoint inhibitors (ICIs), has become a preferred first-line treatment for advanced HCC. However, the overall effectiveness of ICIs in patients with infiltrative HCC remains unclear. This study aims to compare the effect of ICI treatment on clinical outcomes between patients with infiltrative and non-infiltrative HCC.

Materials And Methods: A retrospective cohort consisting of unresectable HCC patients who underwent immunotherapy with ICIs, categorized into infiltrative and non-infiltrative groups was studied. Primary outcomes comprised treatment response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, progression-free survival (PFS), and overall survival (OS).

Results: Of 198 patients, 60 (30.3%) had infiltrative HCC, while 138 (69.7%) had non-infiltrative HCC. In the infiltrative group, the objective response rate (ORR) was 36.7% and the disease control rate (DCR) was 55.0%. For the non-infiltrative group, the ORR was 33.3% and the DCR was 56.5%, showing no significant difference between the two groups. However, patients in the infiltrative group had significantly shorter median of PFS and OS following immunotherapy, with a PFS of 4.1 months (95% CI: 2.5-6.7;  = 0.0409) and an OS of 10.4 months (95% CI: 6.7-14.4;  = 0.0268), compared with the non-infiltrative group, which had a PFS of 5.5 months (95% CI: 3.2-7.6) and an OS of 17.0 months (95% CI: 12.8-21.8).

Conclusion: For immunotherapy, infiltrative HCC exhibits treatment responses similar to non-infiltrative HCC. Nonetheless, infiltrative HCC is associated with shorter survival outcomes, compared with non-infiltrative type. Our findings emphasize the essential of considering type discrepancies when developing management strategies for immunotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719450PMC
http://dx.doi.org/10.1177/17588359241312141DOI Listing

Publication Analysis

Top Keywords

infiltrative hcc
16
patients infiltrative
12
infiltrative
10
hcc
9
hepatocellular carcinoma
8
non-infiltrative
8
hcc associated
8
infiltrative non-infiltrative
8
non-infiltrative hcc
8
hcc infiltrative
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!